Byrnes DM, et al. - One hundred nine consecutive adult patients were investigated for the incidence of neurologic and nonneurologic side effects secondary to intrathecal (IT) chemotherapy over a two-year time period. These patients received 355 IT chemotherapy treatments; paresthesias or paralysis, which is defined as significant neurologic events in this analysis was reported in 11 (3.10%). At least one of the minor events such as back pain, headache, fever, vomiting, and asthenia, was reported after 30.70% of IT chemotherapy doses. In view of the findings, researchers recommend clinicians involved in the care of patients receiving IT chemotherapy to consider treatment options lower rate of neurotoxicity such as high-dose systemic methotrexate.